Cutaneous amyloidosis associated with amyopathic dermatomyositis.
Yoshinori
Y
Taniguchi
Taro
T
Horino
Yoshio
Y
Terada
D000284:Administration, Oral; D000682:Amyloid / Q000378:metabolism; D000686:Amyloidosis / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D003882:Dermatomyositis / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007275:Injections, Intravenous; D017563:Lung Diseases, Interstitial / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D020551:Pulse Therapy, Drug; D012867:Skin / Q000378:metabolism / Q000473:pathology*; D016896:Treatment Outcome
D000682:Amyloid; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone; D008775:Methylprednisolone